German device industry sets out requirements for growth
This article was originally published in Clinica
Despite being the world's third largest market, with a turnover growth of 5.4% in 2001, the Euro14 billion ($12.4 billion) German medical device market lags behind that of France and the UK with 6% growth and further behind the US, with 7%. Speaking at the German medical device industry association's (BVMed) annual members meeting in Hamburg last week, BVMed chairperson Cornelia Groehl (Johnson & Johnson/Ethicon) set out the association's views on creating the ideal climate for industry growth. Whereas her speech was not intended to place pressure on the government, it may have this effect in view of the forthcoming general election.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.